(Q73483382)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9210603%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

meta-analysis

0 references

title

The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9210603%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

1 reference

1 reference

1 reference

C Cammà

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9210603%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

M Giunta

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9210603%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

C Linea

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9210603%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

L Pagliaro

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9210603%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

publication date

1 June 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9210603%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

published in

Journal of Hepatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9210603%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9210603%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

1187-1199

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9210603%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9210603%20AND%20SRC:MED&resulttype=core&format=json

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Classification of chronic viral hepatitis: a need for reassessment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

The pathology of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

The nomenclature of chronic active hepatitis: an obituary.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Long-term follow-up of chronic post-transfusion non-A, non-B hepatitis: clinical and histological outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Long-term follow-up of chronic hepatitis non-A, non-B - with special reference to hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Non-A, non-B post-transfusion hepatitis. Looking back in the second decade

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Chronic non-A, non-B hepatitis developed after transfusions, illicit self-injections or sporadically. Outcome during long-term follow-up--a comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Randomised trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

alpha-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Transfusion-associated chronic hepatitis C: Alpha-n1 interferon for 6 vs. 12 months

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Histological outcome of chronic hepatitis C treated with a 12-month course of lymphoblastoid alfa interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: gamma GT levels predictive for response

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Randomized, double-blind, placebo-controlled trial of eight-week course of recombinant ?-interferon for chronic non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Long-term titrated recombinant interferon-alpha 2a in chronic hepatitis C: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Histologically advanced chronic hepatitis C treated with recombinant alpha-interferon: a randomized placebo-controlled double-blind cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Histologic changes in liver biopsy specimens produced by recombinant interferon alpha-2b therapy for chronic non-A,non-B viral hepatitis. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa-2b for nine months

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Interferon therapy in chronic hepatitis C. Evaluation of a low dose maintenance schedule in responder patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Recombinant human interferon alfa-2a in community-acquired non-A, non-B chronic active hepatitis. Preliminary results of a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B/C hepatitis: long-term outcome and effect of increased interferon doses in non-responders

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Prevention of relapse in patients with chronic non-A, non-B/C hepatitis who respond to alpha-interferon. A controlled multicenter trial of low-dose maintenance therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

alpha-Interferon treatment of chronic hepatitis C: a controlled, multicentre, prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Two dose regimens of recombinant interferon-alpha-2b in chronic hepatitis C virus infection. Biochemistry, hepatitis C virus RNA, and liver histology as response indices

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Meta-analyses of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Prediction of response to interferon in patients with chronic active hepatitis C, and evidence that this improves hepatic metabolic function

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Decrease in Serum Hepatitis C Viral RNA during Alpha-Interferon Therapy for Chronic Hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Interferon therapy of cryptogenic chronic active liver disease and its relationship to anti-HCV

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

High dose interferon treatment in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Short and long-term effects of interferon on serum markers of hepatitis C virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Changes of serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Interferon alfa for chronic hepatitis C in haemophiliacs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

[Current status of treatment for chronic viral hepatitis using recombinant interferon alpha]

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Antiviral effect of lymphoblastoid interferon-alpha on hepatitis C virus in patients with chronic hepatitis type C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Can the response to interferon treatment be predicted in patients with chronic active hepatitis C?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alpha 2b

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Benelux multicentre trial of alpha interferon treatment for chronic hepatitis C: standard v high dose treatment monitored by biochemical and virological markers (interim analysis). Benelux Multicentre Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Efficacy of different regimens of interferon alfa-2b treatment in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

A randomized, controlled trial of weekly administration of lymphoblastoid interferon in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Results of long term interferon treatment in non A non B/C chronic active hepatitis. The French Group for the study of NANB/C chronic hepatitis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Treatment of type C chronic active hepatitis with interferon-alpha 2a. Treatment duration does not influence biochemical remission but does decrease the relapse rate

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Français pour l'Etude du Traitement des Hépatites Chroniques NANB/C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Viral and host factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

Efficacy of longterm interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980451-5

7 January 2021

10.1016/S0168-8278(97)80451-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9210603%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference